Search for Articles:
Title / Keyword
Author / Affiliation / Email
Journal
Article Type
 
 
Advanced Search
 
Section
Special Issue
Volume
Issue
Number
Page
 
8.8
4.4
Journals
Cancers
Special Issues
Molecular Pathology and Human Cancers
share announcement

Molecular Pathology and Human Cancers

A special issue of Cancers (ISSN 2072-6694). This special issue belongs to the section "Cancer Pathophysiology".

Deadline for manuscript submissions: 31 December 2025 | Viewed by 666

Special Issue Editors

Dr. Stefano Marletta

E-Mail Website
Guest Editor
1. Division of Pathology, Humanitas Istituto Clinico Catanese, Catania, Italy
2. Department of Diagnostic and Public Health, Section of Pathology, University of Verona, Verona, Italy
Interests: pathology; uropathology; breast pathology; molecular pathology; digital pathology; immunohistochemistry
Dr. Alessandro Russo

E-Mail Website1 Website2
Guest Editor
Medical Oncology Department, Humanitas Istituto Clinico Catanese, Catania, Italy
Interests: lung cancer; oncology; molecular pathology; genomic profiling; immunotherapy
Dr. Giuliana Pavone

E-Mail Website
Guest Editor
1. Department of Clinical and Experimental Medicine, University of Catania, Catania, Italy
2. Medical Oncology Department, Humanitas Istituto Clinico Catanese, Catania, Italy
Interests: breast cancer; oncology; molecular pathology; liquid biopsy, target therapy

Special Issue Information

Dear Colleagues,

In the modern era of personalized medicine, molecular cancer signatures have played a pivotal role along with traditional pathology in guiding cancer diagnosis and patient-tailored therapies. Herein, we propose a Special Issue dedicated to "Molecular Pathology and Human Cancers", aiming to explore the latest advancements and research in this critical field. This issue will cover a wide range of topics, including the molecular mechanisms underlying cancer development, novel diagnostic biomarkers, and innovative therapeutic strategies. By bringing together cutting-edge research and expert reviews, we aim to provide a comprehensive overview of how molecular pathology is transforming our understanding and treatment of human cancers. This Special Issue will serve as a valuable resource for researchers, clinicians, and healthcare professionals dedicated to improving cancer diagnosis, prognosis, and therapy.

Dr. Stefano Marletta
Dr. Alessandro Russo
Dr. Giuliana Pavone
Guest Editors

Manuscript Submission Information

Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.

Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Cancers is an international peer-reviewed open access semimonthly journal published by MDPI.

Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2900 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.

Keywords

  • molecular pathology
  • cancer pathogenesis
  • targeted therapy
  • personalized medicine
  • cancer signaling

Benefits of Publishing in a Special Issue

  • Ease of navigation: Grouping papers by topic helps scholars navigate broad scope journals more efficiently.
  • Greater discoverability: Special Issues support the reach and impact of scientific research. Articles in Special Issues are more discoverable and cited more frequently.
  • Expansion of research network: Special Issues facilitate connections among authors, fostering scientific collaborations.
  • External promotion: Articles in Special Issues are often promoted through the journal's social media, increasing their visibility.
  • Reprint: MDPI Books provides the opportunity to republish successful Special Issues in book format, both online and in print.

Further information on MDPI's Special Issue policies can be found here.

Published Papers (1 paper)

Order results
Result details
Show export options expand_more Show export options expand_less
Select all
Export citation of selected articles as:

Research

11 pages, 1481 KiB  
Article
Efficacy and Safety Analysis of Nab-Paclitaxel Treatment in Elderly Patients with HER-2 Negative Metastatic Breast Cancer: NEREIDE Study
by Giuseppina Rosaria Rita Ricciardi, Alessandro Russo, Maria Vita Sanò, Angela Prestifilippo, Antonio Russo, Vittorio Gebbia, Livio Blasi, Dario Giuffrida, Giuseppa Scandurra, Antonio Savarino, Alfredo Butera, Nicolò Borsellino, Francesco Verderame, Michele Caruso and Vincenzo Adamo
Cancers 2025, 17(13), 2069; https://doi.org/10.3390/cancers17132069 - 20 Jun 2025
Viewed by 396
Abstract
Background: Older women represent a significant and increasing population of patients with breast cancer, accounting for over 40% of new cases of breast cancer. However, this growing subgroup of patients is still underrepresented in clinical trials, and treatment is usually selected based [...] Read more.
Background: Older women represent a significant and increasing population of patients with breast cancer, accounting for over 40% of new cases of breast cancer. However, this growing subgroup of patients is still underrepresented in clinical trials, and treatment is usually selected based on limited data from retrospective subgroup analyses. However, the ESMO guidelines for metastatic breast cancer (mBC) suggest that the management decision should not be based on age alone. Nab-paclitaxel (nab-P) was associated with improved efficacy and a better safety profile than solvent-based taxanes without steroid or antihistamine premedication, making this treatment appealing to elderly patients. Patients and methods: This is an observational, retrospective, multicenter study, evaluating the safety and activity of nab-paclitaxel (nab-P) in elderly patients (≥65 years old) with HER2-negative mBC from 11 Sicilian oncology centers. The primary endpoint of the study was the safety nab-P in elderly mBC patients; secondary endpoints included the overall response rate (ORR), progression-free survival (PFS), and overall survival (OS). Results: We included 70 patients, and all were evaluable for safety and efficacy. All patients had previously been pretreated with taxane-based chemotherapy in a (neo)-adjuvant or metastatic setting. One third of the patients received nab-P as a fourth line therapy. Most of the patients were treated with nab-P at doses of 260 mg/m2 3-weekly (87.1%), and 12.9% received a nab-P dose of 125 mg/m2 weekly. Patients’ characteristics included a median age of 67 years (range 65–83 years), a median ECOG PS of 1 (range 0–2), and the following intrinsic molecular subtypes: Luminal A (18.8%), Luminal B HER-2 negative (62.5%), and triple negative (18.8%). Nab-P was administered for a median of six cycles (range 1–21), with 35.5% of patients experiencing a dose reduction, and 11.5% treatment discontinuation due to toxicity. Adverse events were mainly G2-G3 and occurred mostly in patients treated with 3-weekly nab-P (85.7%). The ORR was 31.3% (CR in 6.3% and PR in 25% of pts) and the DCR was 70.4%. Median PFS was 6 months (95% CI, 2–38), and median OS was 40.5 months (95% CI, 7–255). Conclusions: Our real-life study showed that nab-P is an effective, well-tolerated regimen in elderly mBC patients, including taxane-pretreated patients, and can be safely administered in elderly mBC patients. Full article
(This article belongs to the Special Issue Molecular Pathology and Human Cancers)
►▼ Show Figures

Figure 1

Show export options expand_more Show export options expand_less
Select all
Export citation of selected articles as:
 
Displaying articles 1-1
Back to TopTop